Thyroid hormone receptor-beta agonist GC-1 inhibits Met- β-catenin driven hepatocellular cancer.

CONCLUSION: GC-1 exerts a notable antitumoral effect on hMet-S45Y-β-catenin HCC, by inactivating Met signaling. GC-1 does not promote β-catenin activation in HCC. Thus GC-1 may be safe for use in inducing regeneration during chronic hepatic insufficiency.
PMID: 28807594 [PubMed - as supplied by publisher]

Source: The American Journal of Pathology - August 11, 2017 Category: Pathology Authors: Puliga E, Min Q, Tao J, Zhang R, Pradhan-Sundd T, Poddar M, Singh S, Columbano A, Yu J, Monga SP Tags: Am J Pathol Source Type: research